Biblio Discovery — Demo Discovery Service

15 results for "Meletios Athanasios Dimopoulos"

Showing 1–15 · 0.53 seconds · RSS

  1. Journal Article Full text

    Hematological findings and complications of COVID ‐19

    Evangelos Terpos; Ioannis Ntanasis‐Stathopoulos; Ismaı̈l Elalamy et al.

    American Journal of Hematology · 2020 · English · OpenAlex Scopus

    COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in…

  2. Journal Article Full text

    Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

    Ioannis P. Trougakos; Kimon S. Stamatelopoulos; Evangelos Terpos et al.

    Journal of Biomedical Science · 2021 · English · OpenAlex Scopus

    BACKGROUND: Gaining further insights into SARS-CoV-2 routes of infection and the underlying pathobiology of COVID-19 will support the design of rational treatments targeting the life cycle of the virus and/or the adverse effects (e.g., multi-organ collapse) that are triggered by COVID-19-mediated…

  3. Journal Article

    Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients

    Cristina Bergamaschi; Evangelos Terpos; Margherita Rosati et al.

    Cell Reports · 2021 · English · OpenAlex Scopus

    Early responses to vaccination are important for shaping both humoral and cellular protective immunity. Dissecting innate vaccine signatures may predict immunogenicity to help optimize the efficacy of mRNA and other vaccine strategies. Here, we characterize the cytokine and chemokine responses to…

  4. Journal Article Full text

    A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

    Nikhil C. Munshi; Hervé Avet‐Loiseau; Kenneth Carl Anderson et al.

    Blood Advances · 2020 · English · OpenAlex Scopus

    The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS) and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma (MM) using a systematic literature review and meta-analysis. Medline and EMBASE databases were searched for articles…

  5. Journal Article Full text

    Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

    Nizar Jacques Bahlis; Meletios Athanasios Dimopoulos; Darrell J. White et al.

    Leukemia · 2020 · English · OpenAlex Scopus

    Abstract In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM). Updated efficacy and safety after >3 years of follow-up are…

  6. Journal Article Full text

    International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    María‐Victoria Mateos; Shaji Kunnathu Kumar; Meletios Athanasios Dimopoulos et al.

    Blood Cancer Journal · 2020 · English · OpenAlex Scopus

    Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM…

  7. Journal Article Full text

    A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

    Constantine Si Lun Tam; Stephen Opat; Shirley D’Sa et al.

    Blood · 2020 · English · OpenAlex Scopus

    Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in…

  8. Journal Article Full text

    Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Pieter Sonneveld; Meletios Athanasios Dimopoulos; Mario Boccadoro et al.

    New England Journal of Medicine · 2023 · English · OpenAlex Scopus

    BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly…

  9. Journal Article Full text

    Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Michèle Cavo; Francesca Gay; Meral Beksaç et al.

    The Lancet Haematology · 2020 · English · OpenAlex Scopus

    Background The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib–melphalan–prednisone…

  10. Journal Article Full text

    Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

    Efstathios Kastritis; Giovanni O. Palladini; Monique C. Minnema et al.

    New England Journal of Medicine · 2021 · English · OpenAlex Scopus

    BACKGROUND: Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. METHODS: We randomly assigned patients with…